NICE withdraws backing for 'life-transforming' asthma drug

The UK's drug watchdog is set to revoke its approval of a treatment for severe asthma after a fresh review of the evidence, prompting strong criticism from GPs and charities.

NICE: charities concerned after backing for asthma drug withdrawn
NICE: charities concerned after backing for asthma drug withdrawn

Omalizumab had been approved by NICE to treat severe, persistent allergic asthma in adults in 2007, although it was rejected for use in children.

But now NICE has withdrawn its recommendation in updated draft guidance, saying the drug is 'not as clinically or cost-effective as was first thought'.

Charity Asthma UK called the decision 'surprising and disappointing'.

Severe persistent allergic asthma affects over 14,000 people in the UK. Omalizumab, branded as Xolair and administered by injection, is prescribed by specialists when standard treatments such as high-dose corticosteroids or long-acting beta-2 agonists have failed to control symptoms. It has been shown to cut hospital admissions by 61%.But a new analysis published today in draft form does not recommend omalizumab for use by the NHS. It again rejected its use in children.

Although treatments can still be prescribed without NICE approval, commissioners have often clamped down on this activity in the past.

'Retrograde step'
Leicestershire GP and Primary Care Respiratory Society member Dr Dermot Ryan said the decision was a 'retrograde step'.  'For those people who respond, it has been absolutely life-transforming, stopping them from ending up in hospital and allowing them to go back to work,' he said.

He criticised NICE for focusing more on budgets than patient care. 'I think there's more to medicine than just the sums involved. It's very clear there are a small number of people who benefit from this medication. More expensive treatments with less defined benefits seem to be approved. This decision can only move to undermine NICE's credibility with the health profession.'

Asthma UK chief executive Neil Churchill said: 'There is no doubt that without it, more people with asthma will suffer frequent life-threatening asthma attacks and disabling daily symptoms. We find it hard to understand why NICE wants to change its previous recommendation when there is no major new evidence to suggest that it is any less effective than was previously thought.'

The drug costs around £8,000 per patient per year. Around 2,000 people are thought to be taking omalizumab, while a further 2,000 could benefit from the drug.

The treatment is available in Scotland as it was approved for restricted use by the Scottish Medicines Consortium in June 2011.

Sir Andrew Dillon, NICE chief executive, said the committee behind the guidance 'is aware that severe, persistent allergic asthma can have a detrimental effect on a person’s life' and that omalizumab is an effective treatment. 'But new evidence that has become available since our original appraisal of omalizumab in 2007 indicates that it is not as clinically or cost-effective as was first thought,' he said.

NICE will now run a consultation on the guidance and make a final decision in April.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GPs should ignore calls to throw away usable COVID-19 vaccine, says RCGP

GPs should ignore calls to throw away usable COVID-19 vaccine, says RCGP

Suggestions that vaccination sites should throw away usable doses of COVID-19 vaccine...

GPs urged to use influence to dispel COVID-19 vaccine myths and boost BAME uptake

GPs urged to use influence to dispel COVID-19 vaccine myths and boost BAME uptake

GPs have been encouraged to use their ‘huge influence’ to bust misinformation around...

Six in 10 over-80s vaccinated against COVID-19 as figures expose regional variation

Six in 10 over-80s vaccinated against COVID-19 as figures expose regional variation

Six in 10 people aged over 80 in England received a first dose of COVID-19 vaccine...

Summary of changes to the GP contract 2021/22

Summary of changes to the GP contract 2021/22

The BMA and NHS England have agreed minor changes to the GP contract for 2021/22....

Minor changes agreed to GP contract for 2021/22 amid ongoing pandemic pressure

Minor changes agreed to GP contract for 2021/22 amid ongoing pandemic pressure

Changes to the GP contract for 2021/22 will be 'minimal' under a deal struck between...

What's coming up at the RCGP 2021 online conference - Dr David R Williams confirmed

What's coming up at the RCGP 2021 online conference - Dr David R Williams confirmed

The RCGP two-day virtual event takes place next month with keynote speaker Dr David...